Genuity Science

Executive Summary

Genuity Science is a Dublin-based biotechnology company founded in 2014 that specializes in generating and analyzing large-scale, deeply phenotyped whole genome datasets to accelerate precision medicine. The company provides clinico-omic data and analytical insights to pharmaceutical and biotech clients, supporting target discovery, biomarker identification, and clinical trial optimization. Its focus areas include central nervous system (CNS), cardiometabolic, and inflammatory diseases. By leveraging proprietary genomic datasets and advanced analytics, Genuity Science aims to de-risk drug development and improve patient outcomes through data-driven precision medicine approaches. As a private entity, Genuity Science operates in the rapidly growing field of genomics and data-driven drug discovery. The company's value proposition lies in its ability to integrate phenotypic and genomic data at scale, offering unique insights for complex diseases. While the company has not disclosed funding or valuation details, its strategic focus on high-need therapeutic areas positions it well for partnerships with major pharmaceutical players. The growing adoption of precision medicine and increasing demand for real-world genomic data suggest favorable market tailwinds. However, as a private company with limited public information, the conviction score is moderate, reflecting both the potential and uncertainty inherent in early-stage precision medicine platforms.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership for CNS or cardiometabolic programs70% success
• Q4 2026Series B or C funding round to expand platform capabilities and dataset scale60% success
• Q1 2027Release of a new dataset or platform feature targeting inflammatory diseases50% success